Aryl and heteroaryl compounds, compositions, and methods of use
AssigneeTransTech Pharma, Inc.
InventorsAdnan M. M. Mjalli, Robert C. Andrews, Murty N. Arimilli, Mohan Rao, Mustafa Guzel, Muralidhar Bondlela, Xiao-Chuan Guo, Guoxiang Huang
Life of this patent
Estimating the term…
Abstract
This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. Compounds of Formula (I) may be useful for treating viral infections including orthopox viruses, either alone or in combination with other therapeutic agents.
Claims35
The compound of Formula (I):
- wherein
- c is equal to 0, 1, or 2;
- wherein —CH2—, and —CH2—CH2—, optionally substituted 1 to 4 times with substituent(s) independently selected from the group consisting of:
- -alkyl, -aryl, -alkylene-aryl, -arylene-alkyl, -alkylene-arylene-alkyl, —O-alkyl, —O-aryl, and -hydroxyl;
- G is:
- a substituted oxadiazole:
- wherein R7 is alkyl, aryl, alkylene-sulfonyl-alkyl or alkylene-sulfonyl-aryl;
- wherein
- V is:
- —(CH2)b—O—(CH2)a—, —(CH2)b—N(R8)—(CH2)a—, —(CH2)b—O—, —(CH2)b—N(R8), —(CH2)a—, —CH═CH—(R8)— or a direct bond;
- in which a is equal to 0,1, or 2, b is equal to 1 or 2, and R8 is:
- -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl;
- wherein the —CH2— groups may be optionally substituted 1 to 4 times with a substituent selected from the group consisting of:
- -alkyl, -aryl, -alkylene-aryl, -arylene-alkyl, -alkylene-arylene-alkyl, —O-alkyl, —O-aryl, -hydroxyl, —S-alkyl, and —S-aryl;
- X is:
- —N(R9)—, -CON(R9)—, —N(R9)CO—, —N(R9)CON(R10)—, —OC(O)N(R8)—, —SO2N(R9)—, —N(R9)SO2—, or —N(R9)SO2N(R10)—;
- wherein R9 and R10 are independently selected from the group consisting of:
- -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, -alkylene-arylene-alkyl, and —(CH2)dY—, wherein d is equal to 0, 1, or 2,
- wherein
- Y is:
- -hydrogen, —CO2R11, —CH2OR11, —C(O)—R11, —C(O)NR11R12, —C(R11)═N—O—R12, —NR11R12, or an acid isostere;
- wherein R11 and R12 independently selected from the group consisting of:
- -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, -alkylene-arylene-alkyl, -heterocyclyl, or -heteroaryl;
- Ar1 is an aryl, or fused cycloalkylaryl, wherein Ar1 is optionally substituted 1 to 7 times with substituent(s) independently selected from the group consisting of:
- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -D-R12;
- i) -alkyl;
- j) -aryl;
- k) -cycloalkyl;
- l) -alkylene-aryl;
- m) -alkylene-arylene-aryl;
- n) -alkylene-arylene-alkyl;
- o) -arylene-alkyl;
- p) -arylene-arylene-alkyl;
- q) -D-alkyl;
- r) -D-aryl;
- s) -D-alkylene-aryl;
- t) -D-arylene-alkyl;
- u) -D-alkylene-arylene-aryl;
- v) -D-arylene-arylene-aryl;
- w) -D-alkylene-arylene-alkyl;
- x) -alkylene-D-alkylene-aryl;
- y) -arylene-D-alkyl;
- z) -alkylene-D-aryl;
- aa) -alkylene-D-cycloalkyl;
- bb) -alkylene-D-arylene-alkyl;
- cc) -alkylene-D-alkylene-arylene-alkyl;
- dd) -alkylene-D-alkyl;
- ee) -alkylene-D-R13;
- ff) -arylene-D-R13;
- and
- gg) -hydrogen;
- wherein D is —CH2—, —O—, —N(R14)—, —C(O)—, —CON(R14)—, —N(R14)C(O)—, —N(R14)CON(R15)—, —N(R14)C(O)O—, —OC(O)N(R14)—, —N(R14)SO2—, —SO2N(R14)—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O2)—, —N(R14)SO2N(R15)—,
- wherein
- R13, R14, R15, and R16 are independently selected from the group consisting of:
- -hydrogen, hydroxyl, -cyano, nitro, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;
- and
- Ar2 is an aryl group, wherein Ar2 is optionally substituted 1 to 7 times with substituent(s) independently selected from the group consisting of:
- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -T-R17;
- i) -alkyl;
- j) -aryl;
- k) -cycloalkyl;
- l) -alkylene-aryl;
- m) -alkylene-arylene-aryl;
- n) -alkylene-arylene-alkyl;
- o) -arylene-alkyl;
- p) -arylene-arylene-alkyl;
- q) -T-alkyl;
- r) -T-aryl;
- s) -T-alkylene-aryl;
- t) -T-arylene-alkyl;
- u) -T-alkylene-arylene-aryl;
- v) -T-arylene-arylene-aryl;
- w) -T-alkylene-arylene-alkyl;
- x) -alkylene-T-alkylene-aryl;
- y) -arylene-T-alkyl;
- z) -alkylene-T-aryl;
- aa) -alkylene-T-cycloalkyl;
- bb) -alkylene-T-arylene-alkyl;
- cc) -alkylene-T-alkylene-arylene-alkyl;
- dd) -alkylene-T-alkyl;
- ee) -alkylene-T-R17;
- ff) -arylene-T-R17;
- or
- gg) -T-fused cycloalkylaryl;
- and
- hh) -T-fused arylcycloalkyl;
- wherein
- T is a direct bond, —CH2—, —O—, —N(R18)—, —C(O)—, —CON(R18)—, —N(R18)C(O)—, —N(R18)CON(R19)—, —N(R18)C(O)O—, —OC(O)N(R18)—, —N(R18)SO2—, —SO2N(R18)—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O2)—, —N(R18)SO2N(R19)—,
- wherein R17, R18, R19 and R20, are independently selected from the group consisting of:
- -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;
- and wherein
- the alkyl, aryl, alkylene, and arylene groups in Ar1, Ar2, G, R1-R21, may be optionally substituted 1 to 4 times with substituent(s) independently selected from the group consisting of:
- a) -hydrogen;
- b) -fluoro;
- c) -chloro;
- d) -bromo;
- e) -iodo;
- f) -cyano;
- g) -nitro;
- h) -perfluoroalkyl;
- i) -Q-R22;
- j) -Q-alkyl;
- k) -Q-aryl;
- l) -Q-alkylene-aryl;
- m) -Q-alkylene-NR23R24;
- and
- n) -Q-alkyl-W-R25;
- wherein
- Q and W are independently selected from the group consisting of:
- —CH2—, —O—, —N(R26)—, —C(O)—, —CON(R26)—, —N(R26)C(O)—, —N(R26)CON(R27)—, —N(R26)C(O)O—, —OC(O)N(R26)—, —N(R26)SO2—, —SO2N(R26)—, —C(O)—O—, —O—C(O)—, and —N(R26)SO2N(R27)—, wherein
- R22, R23, R24, R25, R26 and R27, are independently selected from the group consisting of:
- -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl,
- or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a compound of Formula (I)
- wherein
- c is equal to 0, 1, or 2;
- wherein —CH2—, and —CH2—CH2—, are optionally substituted 1 to 4 times with substituent(s) independently selected from the group consisting of:
- -alkyl, -aryl, -alkylene-aryl, -arylene-alkyl, -alkylene-arylene-alkyl, —O-alkyl, —O-aryl, or -hydroxyl;
- G -is a substituted oxadiazole:
- wherein R7 is alkyl, aryl, alkylene-sulfonyl-alkyl or alkylene-sulfonyl-aryl.
- wherein
- V is:
- —(CH2)b—O—(CH2)a—, —(CH2)b—N(R8)—(CH2)a—, —(CH2)b—O—, —(CH2)b—N(R8), —(CH2)a—, -CH═CH—(CR8)—or a direct bond;
- in which a is equal to 0,1, or 2, b is equal to 1 or 2, and R8 is:
- -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl;
- wherein the —CH2— groups may be optionally substituted 1 to 4 times with a substituent selected from the group consisting of:
- -alkyl, -aryl, -alkylene-aryl, -arylene-alkyl, -alkylene-arylene-alkyl, —O-alkyl, —O-aryl, and -hydroxyl;
- X is:
- —N(R9)—, —CON(R9)—, —N(R9)CO—, —N(R9)CON(R10)—, —OC(O)N(R8)—, —SO2N(R9)—, —N(R9) SO2—, or —N(R9)SO2N(R10)—;
- wherein R9 and R10 are independently selected from the group consisting of:
- -hydrogen, -alkyl, -aryl, arylene-alkyl, -alkylene-aryl, -alkylene-arylene-alkyl, and —(CH2)dY—, wherein d is equal to 0, 1, or 2,
- wherein
- Y is:
- -hydrogen, —CO2R11, —CH2OR11, —C(O)—R11, —C(O)NR11R12, —C(R11)═N—O—R12, —NR11R12, or an acid isostere;
- wherein R11 and R12 independently selected from the group consisting of:
- -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, or -alkylene-arylene-alkyl,
- Ar1 is an aryl, or fused cycloalkylaryl, wherein Ar1 is optionally substituted 1 to 7 times with substituent(s) independently selected from the group consisting of:
- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -D-R12;
- i) -alkyl;
- j) -aryl;
- k) -cycloalkyl;
- l) -alkylene-aryl;
- m) -alkylene-arylene-aryl;
- n) -alkylene-arylene-alkyl;
- o) -arylene-alkyl;
- p) -arylene-arylene-alkyl;
- q) -D-alkyl;
- r) -D-aryl;
- s) -D-alkylene-aryl;
- t) -D-arylene-alkyl;
- u) -D-alkylene-arylene-aryl;
- v) -D-arylene-arylene-aryl;
- w) -D-alkylene-arylene-alkyl;
- x) -alkylene-D-alkylene-aryl;
- y) -arylene-D-alkyl;
- z)-alkylene-D-aryl;
- aa) -alkylene-D-cycloalkyl;
- bb) -alkylene-D-arylene-alkyl;
- cc) -alkylene-D-alkylene-arylene-alkyl;
- dd) -alkylene-D-alkyl;
- ee) -alkylene-D-R13;
- and
- ff) -arylene-D-R13;
- wherein D is —CH2—, —O—, —N(R14)—, —C(O)—, —CON(R14)—, —N(R14)C(O)—, —N(R14)CON(R15)—, —N(R14)C(O)O—, —OC(O)N(R14)—, —N(R14)SO2—, —SO2N(R14)—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O2)—, —N(R14)SO2N(R15)—,
- wherein
- R13, R14, R15, and R16 independently selected from the group consisting of:
- -hydrogen, hydroxyl, -cyano, nitro, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;
- and
- Ar2 is an aryl group, wherein Ar2 is optionally substituted 1 to 7 times with substitutent(s) independently selected from the group consisting of:
- a) -fluoro;
- b) -chloro;
- c) -bromo;
- d) -iodo;
- e) -cyano;
- f) -nitro;
- g) -perfluoroalkyl;
- h) -T-R17;
- i) -alkyl;
- j) -aryl;
- k) -cycloalkyl;
- l) -alkylene-aryl;
- m) -alkylene-arylene-aryl;
- n) -alkylene-arylene-alkyl;
- o) -arylene-alkyl;
- p) -arylene-arylene-alkyl;
- q) -T-alkyl;
- r) -T-aryl;
- s) -T-alkylene-aryl;
- t) -T-arylene-alkyl;
- u) -T-alkylene-arylene-aryl;
- v) -T-arylene-arylene-aryl;
- w) -T-alkylene-arylene-alkyl;
- x) -alkylene-T-alkylene-aryl;
- y) -arylene-T-alkyl;
- z) -alkylene-T-aryl;
- aa) -alkylene-T-cycloalkyl;
- bb) -alkylene-T-arylene-alkyl;
- cc) -alkylene-T-alkylene-arylene-alkyl;
- dd) -alkylene-T-alkyl;
- ee) -alkylene-T-R17;
- ff) -arylene-T-R17;
- or
- gg) -T-fused cycloalkylaryl;
- and
- hh) -T-fused arylcycloalkyl;
- wherein
- T is a direct bond, —CH2—, —O—, —N(R18)—, —CON(R18)—, —N(R18)C(O)—, —N(R18)CON(R19)—, —N(R18)C(O)O—, —OC(O)N(R18)—, —N(R18)SO2—, —-SO2N(R18)—, —C(O)—O—, —O—C(O)—, —S—, —S(O)—, —S(O2)—, —N(R18)SO2N(R19)—,
- wherein R17, R18, R19 and R20, are independently selected from the group consisting of:
- -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl;
- and wherein
- the alkyl, aryl, alkylene, and arylene groups in Ar1, Ar2, G, R1-R21, may be optionally substituted 1 to 4 times with substituent(s) independently selected from the group consisting of:
- a) -hydrogen;
- b) -fluoro;
- c) -chloro;
- d) -bromo;
- e) -iodo;
- f) -cyano;
- g) -nitro;
- h) -perfluoroalkyl;
- i) -Q-R22;
- j) -Q-alkyl;
- k) -Q-aryl;
- l) -Q-alkylene-aryl;
- m) -Q-alkylene-NR23R24;
- and
- n) -Q-alkyl-W-R25;
- wherein
- Q and W are independently selected from the group consisting of:
- —CH2—, —O—, —N(R26)—, —C(O)—, —CON(R26)—, —N(R26)C(O)—, —N(R26)CON(R27)—, —N(R26)C(O)O—, —OC(O)N(R26)—, —N(R26)SO2—, —SO2N(R26)—, —C(O)—O—, —O—C(O)—, and —N(R26)SO2N(R27)—, wherein
- R22, R23, R24, R25, R26 and R27, are independently selected from the group consisting of:
- -hydrogen, -alkyl, -aryl, -arylene-alkyl, -alkylene-aryl, and -alkylene-arylene-alkyl,
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.